Buchumschlag

Management of patients undergoing CAR-T cell therapy in Germany

Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally acce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Penack, Olaf (VerfasserIn) , Dreger, Peter (VerfasserIn) , Ajib, Salem (VerfasserIn) , Ayuk, Francis (VerfasserIn) , Baermann, Ben-Niklas (VerfasserIn) , Bug, Gesine (VerfasserIn) , Kriege, Oliver (VerfasserIn) , Jentzsch, Madlen (VerfasserIn) , Kobbe, Guido (VerfasserIn) , Koenecke, Christian (VerfasserIn) , Lutz, Mathias (VerfasserIn) , Martin, Sonja (VerfasserIn) , Schlegel, Paul-Gerhard (VerfasserIn) , Schroers, Roland (VerfasserIn) , von Tresckow, Bastian (VerfasserIn) , Vucinic, Vladan (VerfasserIn) , Subklewe, Marion (VerfasserIn) , Bethge, Wolfgang (VerfasserIn) , Wolff, Daniel (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 2024
In: Oncology research and treatment
Year: 2024, Jahrgang: 47, Heft: 3, Pages: 65-75
ISSN:2296-5262
DOI:10.1159/000536201
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000536201
Volltext
Verfasserangaben:Olaf Penack, Peter Dreger, Salem Ajib, Francis Ayuk, Ben-Niklas Baermann, Gesine Bug, Oliver Kriege, Madlen Jentzsch, Guido Kobbe, Christian Koenecke, Mathias Lutz, Sonja Martin, Paul-Gerhard Schlegel, Roland Schroers, Bastian von Tresckow, Vladan Vucinic, Marion Subklewe, Wolfgang Bethge, Daniel Wolff
Beschreibung
Zusammenfassung:Introduction: Chimeric antigen receptor positive T cell (CAR-T cell) treatment became standard therapy for relapsed or refractory hematologic malignancies, such as non-Hodgkin’s lymphoma and multiple myeloma. Owing to the rapidly progressing field of CAR-T cell therapy and the lack of generally accepted treatment guidelines, we hypothesized significant differences between centers in the prevention, diagnosis, and management of short- and long-term complications. Methods: To capture the current CAR-T cell management among German centers to determine the medical need and specific areas for future clinical research, the DAG-HSZT (Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie; German Working Group for Hematopoietic Stem Cell Transplantation and Cellular Therapy) performed a survey among 26 German CAR-T cell centers. Results: We received answers from 17 centers (65%). The survey documents the relevance of evidence in the CAR-T cell field with a homogeneity of practice in areas with existing clinical evidence. In contrast, in areas with no - or low quality - clinical evidence, we identified significant variety in management in between the centers: management of cytokine release syndrome, immune effector cell-related neurotoxicity syndrome, IgG substitution, autologous stem cell backups, anti-infective prophylaxis, and vaccinations. Conclusion: The results indicate the urgent need for better harmonization of supportive care in CAR-T cell therapies including clinical research to improve clinical outcome.
Beschreibung:Online veröffentlicht: 10. Januar 2024
Gesehen am 13.09.2024
Beschreibung:Online Resource
ISSN:2296-5262
DOI:10.1159/000536201

Ähnliche Einträge